NasdaqGM:TNGXBiotechs
Tango Therapeutics (TNGX) Could Be 64% Below Fair Value As It Adds Robert Azelby
Tango Therapeutics (TNGX) recently appointed biopharmaceutical executive Robert Azelby to its Board of Directors, as the company advances investigational PRMT5 inhibitor vopimetostat toward potential late stage development in pancreatic cancer.
See our latest analysis for Tango Therapeutics.
Tango Therapeutics' share price has recently shown strong momentum, with a 30 day share price return of 43.18% and a year to date share price return of 252.41%. The 1 year total shareholder return is very...